Adelina Hrkac

Dr. Adelina Hrkac

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Dragan PrimoracDragan Primorac
Dragan Primorac
Petar BrlekPetar Brlek
Petar Brlek
Luka BulićLuka Bulić
Luka Bulić
NHNenad Hrvatin
Nenad Hrvatin
VSVedrana Skaro
Vedrana Skaro
Ali MobasheriAli Mobasheri
Ali Mobasheri
Extracellular vesicles (EVs) have emerged as essential mediators of intercellular communication, transporting a complex repertoire of lipids, proteins, and nucleic acids that mirror the physiological and pathological status of their parent cells. This review provides a comprehensive overview of EVs from their biogenesis and molecular composition to their translational potential in human disease. This review outlines the major classes of EVs, including exosomes, microvesicles, apoptotic bodies, and oncosomes, together with recent developments in their isolation, molecular characterization, and omics-based profiling. Special focus is given to the role of EVs in viral infection, inflammation, and immune regulation, as well as their contribution to disease development and cancer biology. Moreover, we highlight the emerging clinical applications of mesenchymal stem cell-derived EVs (MSC-EVs) in regenerative medicine and oncology, alongside the therapeutic modulation of EV signaling by photobiomodulation (PBM). Finally, we address key translational challenges related to standardization, scalability, and regulatory validation. As exosome-based therapeutics fall under strict FDA and EMA oversight, their translation further depends on harmonized quality controls and robust safety evaluation. By integrating molecular mechanisms with clinical applications, this review emphasizes the transformative potential of EVs as next-generation diagnostic and therapeutic tools in precision medicine.

Verified
Journal Article
Open access
PDF file
Dragan PrimoracDragan Primorac
Dragan Primorac
Petar BrlekPetar Brlek
Petar Brlek
Luka BulićLuka Bulić
Luka Bulić
NHNenad Hrvatin
Nenad Hrvatin
VSVedrana Skaro
Vedrana Skaro
Ali MobasheriAli Mobasheri
Ali Mobasheri
Extracellular vesicles (EVs) are membrane-bound nanoparticles released by almost all cell types into the extracellular space, acting as important mediators of intercellular communication by transferring proteins, lipids, and nucleic acids horizontally. EVs are generally classified into small EVs (200 nm), microvesicles, and apoptotic bodies, with current classification methods focusing on physical properties, molecular composition, and cellular origin, as detailed in the MISEV2023 guidelines. EVs are highly promising for diagnostic and therapeutic applications due to their intrinsic biocompatibility, stability in biological fluids, capacity to carry diverse molecular cargo, and potential for drug delivery and functionalization to enable targeted delivery and tissue repair. This narrative review discusses the emerging roles of EVs across various medical fields, including obstetrics and gynecology, ophthalmology, otorhinolaryngology, urology, oncology, orthopedics, neurology, immunology, wound healing, chronic pain management, dermatology, and cardiology. In each discipline, EVs show potential as biomarkers for diagnosing physiological or pathological conditions and as carriers for targeted drug delivery and regenerative treatments. Exosomes, a major type of small EVs, have especially attracted attention as versatile nanocarriers for precision medicine. However, translation into clinical practice requires addressing key pitfalls, including the standardization of isolation and characterization protocols, dose definition, GMP-compliant large-scale production, and regulatory approval. Ongoing interdisciplinary collaboration across disciplines and thorough clinical testing will be essential to unlock the full biomedical potential of EVs and establish them as transformative tools in personalized healthcare.

Verified
Journal Article
Open access
PDF file
AHAdelina Hrkac
Adelina Hrkac
Luka BulićLuka Bulić
Luka Bulić
Petar BrlekPetar Brlek
Petar Brlek
SNSven Nikles
Sven Nikles
PBPero Bokarica
Pero Bokarica
Dragan PrimoracDragan Primorac
Dragan Primorac
Exosomes, nanoscale extracellular vesicles released by virtually all cell types, have emerged as pivotal mediators of intercellular communication and play a crucial role in the pathophysiology of numerous acute and chronic diseases, including a wide spectrum of urological disorders. By acting as sophisticated biological shuttles, exosomes transport a rich and highly specific molecular cargo—comprising proteins, lipids, messenger RNAs, microRNAs, and other nucleic acids—that reflects the physiological or pathological state of their cell of origin. Owing to these unique properties, exosomes are increasingly recognized as promising biomarkers for the diagnosis, prognosis, and monitoring of a broad range of inflammatory, degenerative, and neoplastic diseases. Beyond their diagnostic value, exosomes have attracted considerable attention as therapeutic tools, given their ability to promote tissue regeneration, modulate immune responses, and serve as potential targeted drug-delivery systems for small molecules, biologics, vaccines, and gene-based therapies. Notably, exosomes recapitulate many of the beneficial biological effects traditionally attributed to stem cells, while potentially offering a more practical alternative. As cell-free entities, they may reduce—though not entirely eliminate—several risks associated with cell transplantation, such as uncontrolled proliferation and immune rejection, and they raise fewer ethical concerns, making them attractive candidates for regenerative and precision medicine. In urology, the diagnostic, prognostic, and therapeutic applications of exosomes are rapidly expanding, with particularly promising advances observed in bladder, prostate, and kidney diseases. Growing evidence also supports their relevance in a variety of benign urological conditions, including erectile dysfunction, male infertility, neurogenic bladder, urethral stricture disease, stress urinary incontinence, and bladder pain syndrome. This review synthesizes contemporary knowledge on the biological significance and clinical potential of exosomes in urology, highlighting their emerging role as biomarkers and therapeutics, with a special focus on benign urological disorders. We emphasize that the current evidence base in benign urology is largely preclinical, and that clinical translation, although promising, remains at an early stage.